Medscape
The European Medicines Agency (EMA) has recommended that a new oral agent, Welireg (belzutifan), be granted conditional marketing authorization for treatment of two different diseases: the rare genetic disorder von Hippel-Lindau disease (VHL) and a type of advanced renal cell carcinoma often featuring the same gene fault…
Read More
Europe Approves Its First Drug for Von Hippel-Lindau Tumors
Yuri Pekar
12:20
The European Medicines Agency (EMA) has recommended that a new oral agent, Welireg (belzutifan), be granted conditional marketing authorization for treatment of two different diseases: the rare genetic disorder von Hippel-Lindau disease (VHL) and a type of advanced renal cell carcinoma often featuring the same gene fault…
